This profile was last updated on .
Is this you? Claim your profile.
T3D Therapeutics Inc
68 T.W. Alexander Drive
Research Triangle Park,
T3D Therapeutics Inc. is a privately-held Research Triangle Park, NC-based company incorporated in 2013. The company is committed to developing disease remedial therapeutics for the treatment of Alzheimer's disease and other CNS disorders. T3D-959, its le...
Find other employees at this company (3)
(163 Total References)
"This is a significant milestone for ...
"This is a significant milestone for the company," said John Didsbury, T3D's CEO, in a statement.
received approval from the Food and Drug Administration's
Division of Neurology Products.
In March, T3D
received a $1.8 million federal grant to support the Phase 2 trial, which is expected to involve 36 patients.
T3D-959 has demonstrated encouraging results in experiments with lab rats that hold out the promise that it could slow or even halt the progress of Alzheimer's, Didsbury
said in March.
Founded in 2013, T3D
is a virtual company that relies on outsourcing.
It currently has two full-time and one-part time employee.
T3D-959 was licensed in 2013 from Raleigh's Dara BioSciences, where Didsbury previously was chief scientific officer.
"This is a significant milestone for ...
"This is a significant milestone for our company," said CEO John Didsbury, a former GlaxoSmithKline executive who took his pharmaceutical company experience into the entrepreneurship realm by founding T3D in 2013.
Commenting on the award, T3D ...
Commenting on the award, T3D Therapeutics' CEO John Didsbury said, "The National Institute on Aging's support will enable us to test our novel approach to developing an Alzheimer's disease drug therapy that has the potential to slow, stop or reverse the progression of disease.
T3D Therapeutics, Inc.
John Didsbury is CEO of ...
John Didsbury is CEO of T3D Therapeutics, a startup company that is seeking money to carry a diabetes candidate into studies as a treatment for Alzheimer's disease.
A Research Triangle Park drug development startup company is looking to raise money to further studies of a drug candidate that was originally targeted as a treatment for diabetes as a treatment for Alzheimer's disease.
T3D Therapeutics CEO Dr. John Didsbury said the start-up company licensed a diabetes drug candidate from Dara BioSciences, a Raleigh-based pharmaceutical company focused on cancer supportive care products and on developing cancer treatments.
Didsbury was formerly chief scientific officer at Dara.
"It's been a personal mission of mine to identify and develop a breakthrough medicine for any disease, and this particular drug is the culmination of the search," Didsbury
said of the drug candidate, which he
believes could have multiple mechanisms for treating Alzheimer's.
"It's a tough haul, but one that just requires perseverance and tenacity."
said there are "striking similarities" between diabetes and Alzheimer's.
The company's drug candidate would work in multiple ways by regulating enzymes involved in Alzheimer's defects, he
"It acts in a myriad of ways, and like I said, it regulates the levels of certain key enzymes that are involved in the pathophysiology of the disease," he
Through T3D Therapeutics
is looking to raise money to try to carry the diabetes drug that his company licensed from Dara
into Phase 2 trials.
said the additional funding will allow the company to do some pre-clinical work, but they're still evaluating their financial strategy to figure out a way to pay for Phase 2 trials.
said company has applied for grants from the National Institutes of Health
and other organizations.
he T3D Therapeutics ...
he T3D Therapeutics team, including John Didsbury, who was Chief Scientific Officer of DARA from 2005 to 2009, is comprised of leading experts in the field of PPAR science and are extremely familiar with the compound.
e believe they will apply the necessary resources to explore DB959 in multiple, potential high-value indications.Importantly, the agreement affords DARA upfront considerations as well as future potential revenue based on progression of the DB959 developmental program."
previously reported that it was actively seeking to out-license DB959 as part of its strategic plan to focus on the commercialization of oncology supportive care products.
John Didsbury, Ph.D., Founder and Chief Executive Officer of T3D Therapeutics, commented, "The T3D Therapeutics team has a long history with DB959, and we plan to develop it as a transformational new therapy for the treatment of Alzheimer's disease.Unlike other therapies in development that target a single pathology, typically the reduction or prevention of beta amyloid plaque buildup, T3D expects DB959 will afford a multidimensional opportunity, with the potential to improve several Alzheimer's disease pathologies including addressing beta amyloid plaque issues.Positive improvements in disease pathologies such as neuro-inflammation, neuronal cell loss, neurotransmitter deficits, tau neurofibrillary tangles, and insulin resistance / lowered cerebral glucose metabolism also are anticipated."
continued, "With today's highly competitive diabetes and dyslipidemia market, we believe that DB959 will be better positioned to address unmet medical needs for new central nervous system (CNS) therapies.Given the neuroprotectant potential of DB959's mechanism of action and the growing evidence of metabolic disorders contributing to CNS diseases, we are excited to commence an aggressive development program for DB959."
John Didsbury, Ph.D.